COLO-699

Cat.No.: CSC-C0321

Species: Homo sapiens (Human)

Source: Pleural Effusion Metastasis

Morphology: adherent, epitheloid cells growing as monolayers

Culture Properties: monolayer

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-C0321
Description
Established from the pleural fluid of a 57-year-old woman with adenocarcinoma of the lung in 1986
Species
Homo sapiens (Human)
Source
Pleural Effusion Metastasis
Recommended Medium
Culture Properties
monolayer
Morphology
adherent, epitheloid cells growing as monolayers
Karyotype
Human hypertriploid karyotype with 2% polyploidy - 70(62-72)<3n>XX, -X, +1, +3, -4, +6, +7, +7, +8, -9, -10, +12, -14, -16, -17, -17, +18, +20, der(2)t(2;10)(q27;q12), der(7)t(7;?)(p21;?)x2, i(10q), der(11)t(8;11)(q12;q14), idic(16q), der(21)t(21;?)(p12;?
Disease
Lung Adenocarcinoma
Quality Control
Mycoplasma: negative in DAPI, microbiological culture, RNA hybridization assays
Immunology: cytokeratin -, cytokeratin-7 -, cytokeratin-8 -, cytokeratin-17 -, cytokeratin-18 -, desmin -, endothel -, EpCAM -, GFAP -, neurofilament -, vimentin +; cells are
Storage and Shipping
Frozen with 70% medium, 20% FBS, 10% DMSO at about 1 x 10^6 cells/ampoule; ship in dry ice; store in liquid nitrogen
Synonyms
COLO 699; Colo-699; COLO #699; Colo699; COLO699; Colorado 699; CHL1DM
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

COLO-699 is a human non-small cell lung cancer (NSCLC) cell line established from the pleural effusion of a 58-year-old female patient with lung adenocarcinoma. It grows adherently with an epithelial morphology and faithfully retains the oncogenic driver lesions of its tumor of origin, most notably a homozygous KRAS G12V substitution and a TP53 missense mutation, while remaining wild-type for EGFR and ALK. This genotype positions COLO-699 as a clinically faithful model of the KRAS-driven adenocarcinoma subtype, which represents a substantial fraction of NSCLC cases and has historically proven refractory to conventional targeted agents.

Its derivation from a malignant pleural effusion is a paramount advantage, as the cells inherently harbor transcriptomic programs governing mesothelial invasion, anchorage-independent survival, and resistance to anoikis, thereby providing a unique system for dissecting the molecular determinants of pleural metastasis. COLO-699 is highly tumorigenic in immunocompromised mice, enabling in vivo efficacy testing of systemic and intracavitary therapies. Moreover, the cells are amenable to lentiviral transduction, siRNA-mediated silencing, and CRISPR-Cas9 genome editing, facilitating mechanistic gain- and loss-of-function studies.

Effects of Small Extracellular Vesicles Isolated from Pleural Effusion on Lung Cancer Cell Proliferation and Migration

Pleural effusion (PE) is a common clinical manifestation associated with advanced stages of both malignant and non-malignant diseases. PE frequently occurs in advanced non-small cell lung cancer (NSCLC) and contributes to tumor progression. Extracellular vesicles (EVs) present in PE are emerging as key mediators of intercellular communication, capable of transferring oncogenic signals through their molecular cargo. Among these molecules, microRNAs (miRNAs) are increasingly recognized as important drivers of cancer progression. miR-21 is a representative onco-miRNA, involved in lung cancer progression; moreover EV-miR-21 upregulation at the pre-dissemination stage promotes cancer cell survival in the pleural cavity. This study compares, for the first time, the functional role of EVs isolated from malignant PE in NSCLC patients (NSCLC-PE-EVs) with those isolated from PE in patients with congestive heart failure (CHF-PE-EVs), focusing on their ability to modulate lung cancer cell behavior.

The effects of these EVs were evaluated on COLO699 lung adenocarcinoma cells with proliferation, migration, and gene expression assays. NSCLC-PE was found to contain approximately twice the amount of EVs compared to CHF-PE. NSCLC-PE-EVs were enriched in the oncogenic miR-21-5p, while CHF-PE-EVs had higher levels of the tumor-suppressive miR-126-3p. Only NSCLC-PE-EVs induced dose-dependent increases in COLO699 cell proliferation and migration, consistent with elevated miR-21-5p expression. Functional studies confirmed that miR-21-5p mediates these effects by downregulating PTEN and PDCD4, and by upregulating MMP9 expression.

Confocal microscopy analysis of NSCLC-PE-sEVs internalization by COLO699 cells.

Fig. 1. COLO699 cells internalize NSCLC-PE-sEVs: Confocal microscopy analysis of COLO699 cells treated, for 1 and 3 h, with 20 μg/ml of NSCLC-PE-sEVs (Cammarata, G., et al., 2026).

Effects of miR-21-5p on COLO699 cell proliferation and migration.

Fig. 2. miR-21-5p delivered by NSCLC-PE-sEVs modulates COLO699 cell proliferation and migration (Cammarata, G., et al., 2026).

Ask a Question

Write your own review

  • You May Also Need

For research use only. Not for any other purpose.

Hot Products